Risk assessment of post-LASIK corneal ectasia in refractive surgery patients is now a more exact, objective, evaluation thanks to the work of Heidelberg Engineering and a leading research partner in Paris.
A drug candidate, based on pioneering UCL and Moorfields Eye Hospital research and currently under development by SIFI S.p.A., has been found to be highly effective in treating a rare sight-threatening eye infection in a new international clinical trial.
